FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Venrock Healthcare Capital Partners III, L.P.
2. Issuer Name and Ticker or Trading Symbol

Altimmune, Inc. [ ALT ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O VENROCK, 7 BRYANT PARK, 23RD FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)

5/26/2020
(Street)

NEW YORK, NY 10018
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/26/2020  P  309453 A$8.79 (1)2005817 I By Funds (2)(3)
Common Stock 5/26/2020  P  390547 A$9.78 (4)2396364 I By Funds (3)(5)
Common Stock 5/27/2020  P  125162 A$7.23 (6)2521526 I By Funds (3)(7)
Common Stock 5/27/2020  P  277000 A$7.92 (8)2798526 I By Funds (3)(9)
Common Stock 5/28/2020  P  27763 A$7.79 (10)2826289 I By Funds (3)(11)
Common Stock 5/28/2020  P  173711 A$8.87 (12)3000000 I By Funds (3)(13)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.40 to $9.39, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (4), (6), (8), (10) and (12) to this Form 4.
(2) Represents (a) 1,146,325 shares of common stock held by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (b) 114,532 shares of common stock held by VHCP Co-Investment Holdings III, LLC ("VHCP III Co"), (c) 530,137 shares of common stock held by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), and (d) 214,823 shares of common stock held by VHCP Co-Investment Holdings II, LLC ("VHCP II Co").
(3) VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM II. Dr. Koh, Mr. Shah, VHCPM III and VHCPM II disclaim beneficial ownership over all shares held by VHCP III, VHCP III Co, VHCP II and VHCP II Co, except to the extent of their respective indirect pecuniary interests therein.
(4) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.40 to $10.00, inclusive.
(5) Represents (a) 1,369,523 shares of common stock held by VHCP III, (b) 136,832 shares of common stock held by VHCP III Co, (c) 633,359 shares of common stock held by VHCP II, and (d) 256,650 shares of common stock held by VHCP II Co.
(6) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.63 to $7.62, inclusive.
(7) Represents (a) 1,441,054 shares of common stock held by VHCP III, (b) 143,978 shares of common stock held by VHCP III Co, (c) 666,439 shares of common stock held by VHCP II, and (d) 270,055 shares of common stock held by VHCP II Co.
(8) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.63 to $8.05, inclusive.
(9) Represents (a) 1,599,360 shares of common stock held by VHCP III, (b) 159,795 shares of common stock held by VHCP III Co, (c) 739,650 shares of common stock held by VHCP II, and (d) 299,721 shares of common stock held by VHCP II Co.
(10) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.61 to $8.60, inclusive.
(11) Represents (a) 1,615,227 shares of common stock held by VHCP III, (b) 161,380 shares of common stock held by VHCP III Co, (c) 746,988 shares of common stock held by VHCP II, and (d) 302,694 shares of common stock held by VHCP II Co.
(12) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.61 to $9.00, inclusive.
(13) Represents (a) 1,714,502 shares of common stock held by VHCP III, (b) 171,299 shares of common stock held by VHCP III Co, (c) 792,900 shares of common stock held by VHCP II, and (d) 321,299 shares of common stock held by VHCP II Co.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Venrock Healthcare Capital Partners III, L.P.
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
NEW YORK, NY 10018

X

VHCP Co-Investment Holdings III, LLC
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
NEW YORK, NY 10018

X

VHCP Management III, LLC
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
NEW YORK, NY 10018

X

Venrock Healthcare Capital Partners II, L.P.
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
NEW YORK, NY 10018

X

VHCP Co-Investment Holdings II, LLC
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
NEW YORK, NY 10018

X

VHCP Management II, LLC
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
NEW YORK, NY 10018

X

Koh Bong Y
C/O VENROCK
7 BRYANT PARK 23RD FLOOR
NEW YORK, NY 10018

X

Shah Nimish P
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
NEW YORK, NY 10018

X


Signatures
/s/ David L. Stepp, Authorized Signatory5/28/2020
**Signature of Reporting PersonDate

/s/ Bong Koh5/28/2020
**Signature of Reporting PersonDate

/s/ Nimish Shah5/28/2020
**Signature of Reporting PersonDate

Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Altimmune Charts.
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Altimmune Charts.